Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival

Bush,Stephen H.; Tollin,Sharon; Marchion,Douglas C.; Xiong,Yin; Abbasi,Forough; Ramirez,Ingrid J.; Zgheib,Nadim Bou; Boac,Bernadette; Judson,Patricia L.; Chon,Hye Sook; Wenham,Robert M.; Apte,Sachin M.; Cubitt,Christopher L.; Berglund,Anders E.; Havrilesky,Laura J.; Lancaster,Johnathan M.

doi:10.3892/mco.2016.725

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival

Authors:
- Stephen H. Bush
- Sharon Tollin
- Douglas C. Marchion
- Yin Xiong
- Forough Abbasi
- Ingrid J. Ramirez
- Nadim Bou Zgheib
- Bernadette Boac
- Patricia L. Judson
- Hye Sook Chon
- Robert M. Wenham
- Sachin M. Apte
- Christopher L. Cubitt
- Anders E. Berglund
- Laura J. Havrilesky
- Johnathan M. Lancaster
View Affiliations

Affiliations: Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Translational Research Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Cancer Informatics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Duke University Medical Center, Durham, NC 27710, USA
Published online on: January 7, 2016 https://doi.org/10.3892/mco.2016.725
Pages: 399-404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Experimental and epidemiological data support the potential activity of acetaminophen against ovarian cancer (OVCA). In this study, we sought to confirm the activity of acetaminophen in OVCA cell lines and to investigate the molecular basis of response. A total of 16 OVCA cell lines underwent pretreatment (baseline) genome-wide expression measurements and were then treated with and analyzed for acetaminophen sensitivity. Pearson's correlation analysis was performed to identify genes that were associated with OVCA acetaminophen response. The identified genes were subjected to pathway analysis, and the expression of each represented pathway was summarized using principal component analysis. OVCA acetaminophen response pathways were analyzed in 4 external clinico‑genomic datasets from 820 women for associations with overall survival from OVCA. Acetaminophen exhibited antiproliferative activity against all tested OVCA cell lines, with half maximal inhibitory concentration values ranging from 63.2 to 403 µM. Pearson's correlation followed by biological pathway analysis identified 13 pathways to be associated with acetaminophen sensitivity (P<0.01). Associations were observed between patient survival from OVCA and expression of the following pathways: Development̸angiotensin signaling via β-arrestin (P=0.04), protein folding and maturation̸angiotensin system maturation (P=0.02), signal transduction̸c-Jun N-terminal kinase (JNK) pathway (P=0.03) and androstenedione and testosterone biosynthesis and metabolism (P=0.02). We confirmed that acetaminophen was active against OVCA cells in vitro. Furthermore, we identified 4 molecular signaling pathways associated with acetaminophen response that may also affect overall survival in women with OVCA, including the JNK pathway, which has been previously implicated in the mechanism of action of acetaminophen and is predictive of decreased survival in women with OVCA.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
3	McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
4	Wu YJ, Neuwelt AJ, Muldoon LL and Neuwelt EA: Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res. 33:2391–2400. 2013.PubMed/NCBI
5	Spooner JB and Harvey JG: The history and usage of paracetamol. J Int Med Res. 4(Suppl 4): 1–6. 1976.PubMed/NCBI
6	Ameer B and Greenblatt DJ: Acetaminophen. Ann Int Med. 87:202–209. 1977. View Article : Google Scholar : PubMed/NCBI
7	Botting RM: Mechanism of action of acetaminophen: Is there a cyclooxygenase 3? Clin Infect Dis. 31(Suppl 5): S202–S210. 2000. View Article : Google Scholar : PubMed/NCBI
8	Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ and Swede H: Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 10:903–906. 2001.PubMed/NCBI
9	Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE and Grizzle WE: Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 8:202–209. 2002.PubMed/NCBI
10	Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR and Greenberg ER: Over-the-counter analgesics and risk of ovarian cancer. Lancet. 351:104–107. 1998. View Article : Google Scholar : PubMed/NCBI
11	Baandrup L, Friis S, Dehlendorff C, Andersen KK, Olsen JH and Kjaer SK: Prescription use of paracetamol and risk for ovarian cancer in Denmark. J Natl Cancer Inst. 106:dju1112014. View Article : Google Scholar : PubMed/NCBI
12	Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP and Ness RB: Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 23:311–319. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hannibal CG, Rossing MA, Wicklund KG and Cushing-Haugen KL: Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol. 167:1430–1437. 2008. View Article : Google Scholar : PubMed/NCBI
14	Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, et al: BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 17:6356–6366. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, et al: Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treatment. 119:335–346. 2010. View Article : Google Scholar
16	Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
17	Win S, Than TA, Han D, Petrovic LM and Kaplowitz N: c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem. 286:35071–35078. 2011. View Article : Google Scholar : PubMed/NCBI
18	Johnson GL and Nakamura K: The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease. Biochim Biophys Acta. 1773:1341–1348. 2007. View Article : Google Scholar : PubMed/NCBI
19	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007. View Article : Google Scholar : PubMed/NCBI
20	Czaja MJ: Cell signaling in oxidative stress-induced liver injury. Semin Liver Dis. 27:378–389. 2007. View Article : Google Scholar : PubMed/NCBI
21	Han D, Ybanez MD, Ahmadi S, Yeh K and Kaplowitz N: Redox regulation of tumor necrosis factor signaling. Antioxidants Redox Signal. 11:2245–2263. 2009. View Article : Google Scholar
22	Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA and Kaplowitz N: c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology. 131:165–178. 2006. View Article : Google Scholar : PubMed/NCBI
23	Shibata W, Maeda S, Hikiba Y, Yanai A, Sakamoto K, Nakagawa H, Ogura K, Karin M and Omata M: c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68:5031–5039. 2008. View Article : Google Scholar : PubMed/NCBI
24	Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, et al: c-Jun-NH₂-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 16:184–194. 2010. View Article : Google Scholar : PubMed/NCBI
25	Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 278:19245–19256. 2003. View Article : Google Scholar : PubMed/NCBI